Abstract
Overview: Cannabinoids have gained increasing attention for their therapeutic potential in treating several neurological conditions, including neurodegenerative diseases, chronic pain, and epilepsy. This review aims to assess the current clinical trials investigating cannabinoids, primarily THC and CBD, for neurological disorders. The focus is on the efficacy, safety, and outcome measures used in these trials. Methods: Clinical trials were identified using ClinicalTrials.gov, focusing on studies that examined the effects of cannabinoids in treating neurological conditions. Trials were included if they were Phase 1–4, focused on cannabinoids as primary interventions, and measured relevant outcomes such as pain relief, cognitive function, or spasticity reduction. Data on conditions, interventions, primary and secondary outcomes, and trial phases were extracted and analysed. Results: A total of 47 clinical trials were identified. The most frequently studied conditions were Multiple Sclerosis, Fibromyalgia, and Parkinson’s Disease. Most trials were in Phase 2, with the primary outcome measures focused on pain management, spasticity, and cognitive function. Secondary outcomes primarily included safety and tolerability measures. Thus, cannabinoids, particularly CBD, showed promising results in managing symptoms such as pain and spasticity. Conclusion: The study highlights the broad therapeutic potential of cannabinoids in neurology, with promising results in symptom management for conditions like Multiple Sclerosis and Fibromyalgia.